Neuromuscular Disorders
Conference Coverage
Can an antisense oligonucleotide benefit patients with SOD1-ALS?
PHILADELPHIA – In patients with amyotrophic lateral sclerosis caused by mutations in the SOD1 gene, an investigational treatment reduced SOD1...
FDA/CDC
Ruzurgi approved for Lambert-Eaton myasthenic syndrome in patients under age 17
The approval is the first for a LEMS treatment specifically for pediatric patients.
Conference Coverage
Physical activity slows cognitive decline in patients with Parkinson’s disease
PHILADELPHIA - Higher levels of activity throughout the course of the disease are associated with better cognitive performance.
Conference Coverage
Is pro soccer a risk factor for ALS?
A higher risk of ALS and an earlier age of onset was found among professional soccer players.
Conference Coverage
Myositis mimics: Clues for making the right diagnosis
A number of conditions can mimic myositis, but clues that can point to the correct diagnosis are often present in cases involving the mimics.
From the Journals
Amyloid PET may help facilitate diagnosis of inclusion body myositis
[18F]florbetapir had much greater uptake in muscles of patients with inclusion body myositis, compared with those with polymyositis.
Conference Coverage
Dr. Lisa Christopher-Stine: Polymyositis? It’s more likely something else
Thinking polymyositis? Look closely for IMNM, overlap with other rheumatologic conditions, antisynthetase syndrome, inclusion body myositis, and...
Literature Review
Clinical benefits persist 5 years after thymectomy for myasthenia gravis
Patients with generalized nonthymomatous myasthenia gravis who undergo thymectomy may have better long-term clinical outcomes and require less...
From the Journals
Nuedexta mainly prescribed for dementia, Parkinson’s
Only 15.2% of patients had multiple sclerosis or amyotrophic lateral sclerosis, the diagnoses of patients in the studies leading to the approval...
From the Journals
Motor neuron disease spasticity improved with cannabis-based oral spray, antispasticity drugs
Proof-of-concept trial shows encouraging findings that must be confirmed in larger and longer trials.
News from the FDA/CDC
CDC: Acute flaccid myelitis on the decline for 2018
Pattern of reduced cases in November “appears to be repeating.”